莎普爱思：获硫酸特布他林雾化吸入用溶液《药品注册证书》

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for a nebulized solution of Terbutaline Sulfate, which is intended to alleviate bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1] Company Summary - The approved product is a nebulized solution of Terbutaline Sulfate, which targets respiratory conditions [1] - The cumulative R&D investment for this drug has reached approximately 5.0111 million RMB [1]